S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

$1.48
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.48
$1.48
50-Day Range
$1.43
$1.98
52-Week Range
$0.82
$3.88
Volume
N/A
Average Volume
444,665 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.91

TCR2 Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
232.0% Upside
$4.91 Price Target
Short Interest
Healthy
1.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.69mentions of TCR2 Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$577,108 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.68) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.28 out of 5 stars

Medical Sector

5th out of 983 stocks

Biological Products, Except Diagnostic Industry

2nd out of 164 stocks


TCRR stock logo

About TCR2 Therapeutics (NASDAQ:TCRR) Stock

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Receive TCRR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRR Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Recap: TCR2 Therapeutics Q1 Earnings
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
10-Q: TCR2 THERAPEUTICS INC.
TCR2 Therapeutics' (TCRR) Neutral Rating Reiterated at Wedbush
See More Headlines

TCRR Price History

TCRR Company Calendar

Last Earnings
3/23/2023
Today
6/03/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRR
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.91
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$1.68
Forecasted Upside/Downside
+232.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-151,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
29,443,000
Market Cap
$58.10 million
Optionable
Not Optionable
Beta
1.95

Key Executives

  • Garry E. Menzel
    President, Chief Executive Officer & Director
  • Peter Olagunju
    Chief Operating Officer
  • Eric M. Sullivan
    Chief Financial Officer
  • Alfonso Quintás-Cardama
    Chief Medical Officer
  • Praveen Malhotra
    Vice President-Information Technology













TCRR Stock - Frequently Asked Questions

Should I buy or sell TCR2 Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.
View TCRR analyst ratings
or view top-rated stocks.

What is TCR2 Therapeutics' stock price forecast for 2023?

8 analysts have issued twelve-month price targets for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they expect the company's share price to reach $4.91 in the next twelve months. This suggests a possible upside of 232.0% from the stock's current price.
View analysts price targets for TCRR
or view top-rated stocks among Wall Street analysts.

How have TCRR shares performed in 2023?

TCR2 Therapeutics' stock was trading at $0.9988 at the start of the year. Since then, TCRR shares have increased by 48.2% and is now trading at $1.48.
View the best growth stocks for 2023 here
.

Are investors shorting TCR2 Therapeutics?

TCR2 Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 360,900 shares, a drop of 15.9% from the April 30th total of 429,100 shares. Based on an average daily volume of 602,700 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.2% of the company's shares are sold short.
View TCR2 Therapeutics' Short Interest
.

When is TCR2 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our TCRR earnings forecast
.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.76.

What ETF holds TCR2 Therapeutics' stock ?

Harbor Disruptive Innovation ETF holds 18,131 shares of TCRR stock, representing 0.10% of its portfolio.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.07%), Long Focus Capital Management LLC (1.44%), Renaissance Technologies LLC (1.13%), Citigroup Inc. (0.98%), Long Focus Capital Management LLC (0.91%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Kevin C Tang, Mayur Ian Somaiya, Mpm Asset Management Llc and Robert Hofmeister.
View institutional ownership trends
.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $1.48.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

The company employs 137 workers across the globe.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.

This page (NASDAQ:TCRR) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -